Clinical Trial Update: Golidocitinib Combined With GemOx in RR PTCL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for golidocitinib in combination with GemOx for relapsed/refractory peripheral T-cell lymphoma; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Golidocitinib (golidocitinib)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Ruijin Hospital | Conditions: Peripheral T-cell Lymphomas (PTCL) | Phase 2 | Status: NOT_YET_RECRUITING